GPⅡb/Ⅲa受体拮抗剂在急性冠状动脉综合征中的应用

The Role of GP Ⅱb/Ⅲa Receptor Antagonists in Acute Coronary Syndrome

血小板在动脉粥样硬 化性心血管病的血栓并发症及急性冠状动脉综合征的发生中起了重要作用。血小板的主要作用是在血管损伤部位发生粘附、聚集而形成血栓。血小板膜表面的糖蛋白(GP)Ⅱb/Ⅲa受体与纤维蛋白原连接,并在血小板之间交叉连接完成血小板聚集的最后一步。抗血小板治疗方面最有前途的是血小板GPⅡb/Ⅲa受体拮抗剂。该药的临床试验结果表明,GPⅡb/Ⅲa受体拮抗剂能明显减少接受介入治疗的高危或低危病人的死亡、AMI及血管重建的危险。

Platelet plays a key role in the development of acute coronary syndrome and the thrombotic complications of atherosclerotic cardiovascular disease. The primary role of platelet is to form thrombi by platelet adhesion and aggregation at sites of vessel injury. Glycoprotein (GP) Ⅱb/Ⅲa re-ceptor on the platelet surface membrane, binds circulating fibrinogen and cross-links adjacent platelets as the final common path-way to platelet aggregation. Perhaps the greatest recent advance in antiplatelet therapy has been the development of the platelet GP Ⅱb/Ⅲa receptor antagonists. The clinical trials of GP Ⅱb/Ⅲa receptor antagonists have estab-lished that the use of GP Ⅱb/Ⅲa receptor antagonists could reduce the risk of death, AMI and reintervention across the board in both high and low risk patients undergoing interven-tional procedures.